- Home
- RCUS vs STEW Comparison
RCUS vs STEW Comparison
Compare RCUS & STEW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCUS
- STEW
- Stock Information
- Founded
- RCUS 2015
- STEW 1972
- Country
- RCUS United States
- STEW United States
- Employees
- RCUS N/A
- STEW N/A
- Industry
- RCUS Biotechnology: Pharmaceutical Preparations
- STEW Investment Managers
- Sector
- RCUS Health Care
- STEW Finance
- Exchange
- RCUS Nasdaq
- STEW Nasdaq
- Market Cap
- RCUS 1.4B
- STEW 1.6B
- IPO Year
- RCUS 2018
- STEW N/A
- Fundamental
- Price
- RCUS $14.35
- STEW $16.23
- Analyst Decision
- RCUS Buy
- STEW
- Analyst Count
- RCUS 12
- STEW 0
- Target Price
- RCUS $34.50
- STEW N/A
- AVG Volume (30 Days)
- RCUS 835.5K
- STEW 84.5K
- Earning Date
- RCUS 11-06-2024
- STEW 01-01-0001
- Dividend Yield
- RCUS N/A
- STEW 3.71%
- EPS Growth
- RCUS N/A
- STEW N/A
- EPS
- RCUS N/A
- STEW 1.44
- Revenue
- RCUS $263,000,000.00
- STEW N/A
- Revenue This Year
- RCUS $112.97
- STEW N/A
- Revenue Next Year
- RCUS N/A
- STEW N/A
- P/E Ratio
- RCUS N/A
- STEW $10.34
- Revenue Growth
- RCUS 119.17
- STEW N/A
- 52 Week Low
- RCUS $13.50
- STEW $11.97
- 52 Week High
- RCUS $20.31
- STEW $14.94
- Technical
- Relative Strength Index (RSI)
- RCUS 37.76
- STEW 55.75
- Support Level
- RCUS $14.19
- STEW $16.07
- Resistance Level
- RCUS $15.01
- STEW $16.40
- Average True Range (ATR)
- RCUS 0.98
- STEW 0.19
- MACD
- RCUS -0.22
- STEW 0.01
- Stochastic Oscillator
- RCUS 7.41
- STEW 73.22
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
About STEW SRH Total Return Fund Inc.
SRH Total Return Fund, Inc. is a non-diversified closed-end management investment company. The company's investment objective is to seek total return. Its fund utilizes a bottom-up, value-driven investment process to identify securities of good quality businesses trading below estimated intrinsic value. The Funds are available as an actively-managed closed-end fund, an actively managed ETF and a passively-managed ETF.